PMGC Holdings Inc. Common Stock (ELAB)

FairStock Score: 48/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is offering this tiny biotechnology company at $2.96 as of 2026-10-13, with a $24.0 million market cap and a FairStock P/B of 0.11. That looks statistically cheap, but I have learned to ask what the assets are worth if the business keeps consuming cash. PMGC, doing business as NorthStrive, is trying to develop and acquire aesthetic medicines and therapeutics; its lead asset EL-22 is an engineered probiotic aimed at preserving muscle during weight-loss treatment. It also has IT packaging and precision engineering segments. The latest filed quarter, fiscal Q2 2026 ended 2026-06-30, showed revenue of $1.3 million and a net loss of $2.9 million. The prior filed quarter, fiscal Q1 2026 ended 2026-03-31, had revenue of $681,994 and a net loss of $5.0 million. For FY2025 ended 2025-12-31, revenue was $590,084 and net loss was $7.7 million. FY2024 had a net loss of $6.2 million, and FY2023 had revenue of $1.7 million, a net loss of $4.3 million, and EPS of -$0.40. No profit in four years, negative $9.0 million trailing free cash flow, a FairStock FCF yield of -37.5%, FairStock ROE of -105.22%, ROCE of -32.97%, Piotroski 3/9, Altman Z -0.51, and D/E 0.85 tell me the balance sheet is fragile. The moat is unproven; a 32-person biotech with a development-stage lead asset rarely has durable pricing power. Revenue is growing from tiny levels, but growth without profit is not yet value. A low P/B can be a value trap when losses are persistent. I would need evidence of narrowing losses, positive cash flow, and clinical progress before calling this anything but speculative.

In plain English: PMGC Holdings is a small healthcare company trying to develop and acquire medical and therapeutic products, including a weight-loss-related product, while also running packaging and machining businesses. It is taking in some revenue but losing much more than it makes, so the business looks weak by its own reported results. At $2.96 on 2026-10-13, the stock looks very cheap compared with the value of its assets on its books, but the ongoing losses and cash burn make that cheapness uncertain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer